Loading
SciBrunch Therapeutics is a Shanghai company founded in late 2024 that makes pills for hard-to-treat cancers such as pancreatic and bowel cancer. In September 2026 MSD licensed its KRAS G12D drug, a molecular glue not yet tested in people, for USD 400 million upfront; its PARP1 blocker began its first human trial in January 2026.
SciBrunch Therapeutics, headquartered in Pudong, Shanghai, was founded in late 2024 by serial entrepreneur Tao Hu (chairman and chief executive) and medicinal chemist Yang Zhang (chief scientific officer), with a focus on malignancies such as pancreatic ductal adenocarcinoma and colorectal cancer. Its pipeline comprises SPR1020, a brain-penetrant, highly selective PARP1 inhibitor whose phase 1/2 first-in-human study dosed its first patient on 8 January 2026, for breast, ovarian and prostate cancer and glioma; SPR2015, a molecular glue inhibitor of active (ON-state) KRAS G12D for pancreatic, lung and colorectal cancer; and a KRAS G12V (ON) molecular glue in discovery. On 28 September 2026 it granted MSD (Merck & Co.) an exclusive global licence to SPR2015 for USD 400 million upfront, with total potential value including milestones of USD 2.13 billion. The company raised an angel round of over RMB 200 million in June 2025, co-led by BioTrack Capital and Hankang Capital, and a pre-A round of over USD 35 million in January 2026 led by HighLight Capital.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Pre-Series A · Stated as over USD 35 million; led by HighLight Capital with InnoPinnacle Fund and existing investors | 2026 | $35M | scibrunch.com |
| Angel · Over RMB 200 million; co-led by BioTrack Capital and Hankang Capital with Elikon Venture and LongRiver Investments | 2025 | undisclosed | scibrunch.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/